STARTUP-STORIES

Health-tech Startup Qure.AI Secures $65 Million in Series D Funding to Revolutionize Healthcare with AI-Powered Disease Detection

SUMMARY

1. Qure.AI, an Indian health-tech startup, raised $65 million in a Series D funding round led by Lightspeed Venture Partners and 360 ONE Asset Management, with plans to expand in the US, enhance its AI-driven healthcare solutions, and pursue acquisitions.

2. The company's AI-powered products are used at over 3,000 imaging sites across 90 countries to detect diseases like tuberculosis, lung cancer, and stroke, outperforming human diagnostics. The funds will further develop its generative AI models and improve global healthcare access.

Indian health-tech startup Qure.AI has raised an impressive $65 million in its Series D funding round, led by Lightspeed Venture Partners and 360 ONE Asset Management. The funds will be used to fuel the company's global expansion and further develop its AI-driven healthcare solutions, which are transforming the way diseases are detected and managed.

Expanding AI Capabilities and Global Reach

Qure.AI, founded in 2016 and headquartered in Mumbai, has established itself as a leader in the health-tech space by leveraging artificial intelligence (AI) to diagnose critical diseases. Its innovative products are already in use at more than 3,000 imaging sites across 90 countries, including the United States and Europe. The company’s AI solutions have proven to outperform traditional methods, surpassing human radiologists and physicians in diagnosing life-threatening conditions such as tuberculosis, lung cancer, and stroke.

With fresh funding, Qure.AI plans to expand into new markets—particularly in the US—while enhancing its generative AI foundation models to further refine its diagnostic capabilities. Additionally, the funds will support acquisitions aimed at bolstering its AI-driven portfolio, making it a formidable player in the global healthcare space.

Support from Global Healthcare Investors

The funding round also saw participation from Merck Global Health Innovation Fund and Kae Capital, alongside existing investors such as Novo Holdings, Health Quad, and TeamFund. These well-established investors demonstrate the strong confidence in Qure.AI's vision of advancing AI technology to improve healthcare outcomes globally.

AI: Transforming the Future of Healthcare

The healthcare industry is experiencing a significant transformation with the adoption of AI. Qure.AI’s co-founder and CEO, Prashant Warier, highlighted how AI is addressing key bottlenecks in healthcare by improving diagnosis and patient management. From drug discovery to hospital management and surgical robotics, AI is paving the way for more efficient and accurate healthcare solutions.

Qure.AI’s AI-powered products have already received regulatory clearances in the United States and European Union, making it one of the few startups in the health-tech sector to achieve such a milestone. This latest funding will not only accelerate product development but also strengthen its market position in these regions.

The Future Looks Bright for Qure.AI

As the healthcare industry increasingly turns to artificial intelligence for solutions, Qure.AI is well-positioned to lead the charge. With its cutting-edge AI technologies, the startup is addressing critical global health issues and improving patient outcomes. The recent $65 million funding round will allow Qure.AI to continue its mission of expanding access to quality healthcare, while driving innovation in disease detection and management.